#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13734	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2237	612.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1551	1551	C	861	C,T	784,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25052	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3571	699.4	0	.	n	.	0	T695C	SNP	695	695	T	1003	1003	C	747	C,T	689,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25052	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3571	699.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1645	1645	A	840	A,G	794,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25052	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3571	699.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2279	2279	C	767	C,T	706,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25052	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3571	699.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2353	2353	A	752	A	725	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25052	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3571	699.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2905	2905	C	738	C	686	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1828	folP	852	852	100.0	folP.l15.c4.ctg.1	1562	116.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1006	1008	AGC	192;188;187	A;G,A;C	178;173,1;171	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4778	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3429	139.1	1	SNP	p	S91F	0	.	.	271	273	TCC	601	603	TCC	154;154;154	T;C,T;C	142;140,1;143	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4778	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3429	139.1	1	SNP	p	D95N	0	.	.	283	285	GAC	613	615	GAC	159;162;162	G;A;C,T	147;149;149,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4778	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3429	139.1	1	SNP	p	D95G	0	.	.	283	285	GAC	613	615	GAC	159;162;162	G;A;C,T	147;149;149,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1440	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1224	117.0	1	SNP	p	G45D	1	.	.	133	135	GAC	428	430	GAC	174;175;177	G;A;C	161;157;160	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	784	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1043	74.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4958	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3110	159.1	1	SNP	p	D86N	0	.	.	256	258	GAC	666	668	GAC	202;202;203	G;A;C	182;180;182	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4958	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3110	159.1	1	SNP	p	S87R	0	.	.	259	261	AGT	669	671	AGT	203;202;201	A;G;T	183;181;181	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4958	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3110	159.1	1	SNP	p	S87I	0	.	.	259	261	AGT	669	671	AGT	203;202;201	A;G;T	183;181;181	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4958	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3110	159.1	1	SNP	p	S87W	0	.	.	259	261	AGT	669	671	AGT	203;202;201	A;G;T	183;181;181	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4958	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3110	159.1	1	SNP	p	S88P	0	.	.	262	264	TCC	672	674	TCC	202;205;205	T;C;C	182;189;187	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3900	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2563	151.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1543	1545	GGC	187;187;192	G;G;C	170;169;173	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1270	1272	GCA	190;192;195	G;C,T;A	176;176,1;180	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1273	1275	ATC	196;195;198	A;T;C	180;179;183	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1285	1287	GTG	199;198;196	G;T;G,A	185;185;183,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1285	1287	GTG	199;198;196	G;T;G,A	185;185;183,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1789	1791	ACC	219;219;221	A;C;C	200;202;205	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1843	1845	GCG	191;189;193	G;C,G;G	165;154,1;167	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1843	1845	GCG	191;189;193	G;C,G;G	165;154,1;167	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1966	1968	GGC	163;160;158	G,A,C;G;C	143,1,1;143;140	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1975	1977	GGC	157;156;154	G;G;C	137;140;139	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3576	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2400	148.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1993	1995	CCG	135;139;138	C,G;C,G;G	105,1;110,1;111	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5104	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3031	168.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2140	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1652	128.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	512	512	C	131	C	123	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	V258L	NONSYN	772	774	GTA	99	101	TTA	53;56;54	T;T;A	43;48;45	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	144	146	CAT	44;42;42	C;A;T	39;37;37	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	147	149	AGT	42;42;43	A;G;T	37;37;37	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	156	158	TAC	43;43;44	T;A;C	37;37;38	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	R307E	NONSYN	919	921	AGA	246	248	GAA	16;16;16	G;A;A	16;16;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	258	260	GCA	13;14;13	G;C;A	13;14;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	267	269	ATC	13;13;13	A;T;C	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	273	275	TCG	13;13;13	T;C;G	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	279	281	GCC	13;13;13	G;C;C	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	282	284	AGC	13;13;14	A;G;C	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	285	287	GCC	14;12;12	G;C;C	13;11;11	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	244	porB1a	984	271	92.25	porB1a.l15.c30.ctg.2	389	26.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	291	293	GTT	12;10;10	G;T;T	11;9;9	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2676	porB1b	1035	1035	98.47	porB1b.l15.c4.ctg.1	1438	185.5	0	.	p	.	0	E38G	NONSYN	112	114	GAA	364	366	GGA	227;230;227	G;G;A	213;214;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2676	porB1b	1035	1035	98.47	porB1b.l15.c4.ctg.1	1438	185.5	0	.	p	.	0	V45I	NONSYN	133	135	GTT	385	387	ATT	224;226;231	A;T;T	214;217;219	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2676	porB1b	1035	1035	98.47	porB1b.l15.c4.ctg.1	1438	185.5	0	.	p	.	0	G46S	NONSYN	136	138	GGC	388	390	AGC	230;229;228	A;G;C	218;215;217	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2676	porB1b	1035	1035	98.47	porB1b.l15.c4.ctg.1	1438	185.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	679	681	GGA	247;246;242	G;G;A	217;218;210	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2676	porB1b	1035	1035	98.47	porB1b.l15.c4.ctg.1	1438	185.5	0	.	p	.	0	E210fs	FSHIFT	628	628	G	880	880	G	232	G	212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2676	porB1b	1035	1035	98.47	porB1b.l15.c4.ctg.1	1438	185.5	1	SNP	p	G120K	0	.	.	358	360	GGT	610	612	GGT	219;221;226	G;G;T	202;204;208	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2676	porB1b	1035	1035	98.47	porB1b.l15.c4.ctg.1	1438	185.5	1	SNP	p	A121N	0	.	.	361	363	GCC	613	615	GCC	227;227;227	G;C;C	211;212;214	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2676	porB1b	1035	1035	98.47	porB1b.l15.c4.ctg.1	1438	185.5	1	SNP	p	A121D	0	.	.	361	363	GCC	613	615	GCC	227;227;227	G;C;C	211;212;214	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9530	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4865	195.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1993	1995	AAT	206;205;207	A;A;T	191;190;187	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1024	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1127	90.7	1	SNP	p	V57M	1	.	.	169	171	ATG	601	603	ATG	228;226;226	A;T;G	213;212;211	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
